TEAMLAB
8.8.2019 12:48:06 CEST | Business Wire | Press release
This summer marks the one-year anniversaries for art collective teamLab’s two museums in Tokyo: MORI Building DIGITAL ART MUSEUM: teamLab Borderless (Odaiba, Tokyo; hereafter teamLab Borderless) and teamLab Planets TOKYO (Toyosu, Tokyo; hereafter teamLab Planets). In the one year since their openings, teamLab Borderless and teamLab Planets have seen a combined 3.5 million visitors. teamLab Borderless alone welcomed 2.3 million visitors within one year of opening, exceeding the number of attendees at the Van Gogh Museum in the Netherlands and setting a record number of visitors at a single-artist museum in one year. These visitors came from over 160 countries and regions around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190808005373/en/
teamLab Borderless and teamLab Planets are two museums dedicated solely to art by teamLab. teamLab Borderless is a world of ever-changing artworks without boundaries, a “museum without a map.” One year since its opening in June, 2018, the museum has seen approximately 2.3 million visitors from over 160 countries and regions worldwide. teamLab Planets is “a museum where you move through water.” Guests walk barefoot in the space and physically immerse their entire bodies in massive artworks. One year since its opening in July, 2018, the museum has welcomed over 1.25 million visitors from 106 countries and regions around the world.
When compared to the world’s three most-visited single-artist museums of 2018, both teamLab Borderless and teamLab Planets welcomed more visitors than the Picasso Museum in Barcelona, Spain (948,483 visitors), and the Dalí Theatre-Museum in Figueres, Spain (1,105,169 visitors). The number of museum attendees at teamLab Borderless exceeds even those of the Van Gogh Museum in Amsterdam, Netherlands (2,161,160 visitors), making it the world’s most-visited museum dedicated to a single artist. (*1).
- teamLab Borderless (Odaiba, Tokyo)
Of the 2.3 million visitors to teamLab Borderless, approximately 50% come from overseas (*2), with most coming from the USA, followed by Australia, China, Thailand, Canada, and the UK, making it a museum that attracts not only visitors from neighboring countries, but those from far more distant regions as well. In addition, according to a survey conducted by the museum, it appears that about 50% of the guests from overseas visited Tokyo in order to visit the museum (*3).
- teamLab Planets (Toyosu, Tokyo)
Of the 1.25 million visitors to teamLab Planets, approximately 30% come from overseas (*4), with the majority coming from the USA, followed by Hong Kong, Taiwan, the UK, and Australia.
-----------------------
*1 ”THE ART NEWSPAPER SPECIAL REPORT Art’s Most Popular: Exhibition and museum visitor figures 2018” The Art Newspaper. Number 311, April, 2019.
*2 teamLab Borderless Official Website, Ticket Purchasing Data (data obtained Feb 16 - June 7, 2019)
*3 teamLab Borderless Visitor Survey (conducted Oct 25 - Nov 2, 2018), 1,237 respondents
*4 teamLab Planets Official Website, Ticket Purchasing Data (data obtained March 1 - June 30, 2019)
About teamLab
teamLab (f. 2001) is an art collective, interdisciplinary group of ultratechnologists whose collaborative practice seeks to navigate the confluence of art, science, technology, design and the natural world. teamLab aims to explore a new relationship between humans and nature, and between oneself and the world through art. Click here
for full bio.
teamLab is represented by Pace Gallery
.
Press Kit
teamLab Borderless
https://goo.gl/MpzVss
For tickets and more information, please visit borderless.teamlab.art
, and follow Instagram
.
teamLab Planets
https://goo.gl/tQXMLm
For tickets and more information, please visit planets.teamlab.art
, and follow Instagram
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
